OBJECTIVES: The objective of this analysis is to estimate the budget impact of long-acting insulins Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the treatment of T1DM based on the input of the InRange study, from the Algerian healthcare system perspective assuming only 2^nd Generation basal insulin is used.

METHODS: Budget impact analysis was designed with a 5-years time horizon for patients with T1DM, epidemiology data references were from National office of statistics, IDF and IDMPS wave7, eligible population considered was T1DM adults patients, all treated with 2^nd Generation BI and all are treated with basal insulin. the following inputs were extracted from the InRange RCT (Open label active controlled parallel-group trial): demographics (weight) efficacy outcomes (dose), Safety outcomes (glycemic events). The costs included are treatment costs (price assumptions considered based on local pricing guidelines), direct costs related to the management of severe hypoglycemia (glycemic control costs + assistance costs, transport, healthcare utilization). All costs were reported in euros. Deterministic sensitivity analysis was carried out on all relevant costs and parameters included in the budget impact assessment.

RESULTS: Results showed a negative budget of BI = -70 M € cumulative over 5 years. breakdown of the budget impact per cost category is -52 M € for drug acquisition costs, and -18 M € for costs of managements of glycemic events Sensitivity analyses determined that the proportion of patient population had the potential to impact the base case analysis.

CONCLUSIONS: Results from the present study revealed that Glargine-300U/mL in Algeria reduces the costs of T1DM management. the proportion of eligible patients had considerable influence on the net financial impact. The use of Glargine-300U/mL and the overall of its clinical and economic benefit is the most rational strategy to reduce diabetes burden and its additional costs, Further studies are suggested to confirm this analysis.